How to recognize and act on multiple myeloma relapse

Recognizing multiple myeloma relapse signs early is one of the most powerful tools you have for staying ahead of this disease. According to the International Myeloma Foundation, multiple myeloma is a chronic condition defined by a repeating cycle of remission and recurrence, and understanding that cycle is the first step toward maintaining control over it.

Remission vs. relapse vs. refractory are terms you’ll hear often, and the distinctions matter. Relapsed multiple myeloma means the cancer returned after a period of improvement or response to treatment. Refractory myeloma describes disease that stops responding to a current treatment or never responded at all. Some patients experience both relapsed and refractory myeloma, where the cancer returns and then resists the next line of therapy.

What makes this cycle so challenging is that each relapse can look and feel different. Symptoms may shift, lab values may change gradually, and it’s easy to attribute early warning signs to fatigue or aging. But early detection changes the equation. The sooner a relapse is identified, the faster you and your care team can pivot to new therapies, including advanced options like CAR T-cell therapy, before the disease gains momentum.

Knowledge is leverage here. Knowing which specific signs to watch for gives you the ability to act quickly, communicate clearly with your care team, and access personalized care plan adjustments before symptoms escalate.

The first red flag. New or worsening bone pain

Bone pain is often the earliest and most disruptive sign that multiple myeloma may be returning, and knowing what to look for can make a real difference.

Bone lesions are a hallmark of multiple myeloma disease. Myeloma cells trigger osteoclasts, the cells responsible for breaking down bone tissue, to work overtime, while simultaneously suppressing the cells that rebuild it. The result is bone that weakens faster than the body can repair it. Bone destruction in multiple myeloma relapse may involve lytic lesions or fractures, which some patients and care teams have observed can appear alongside or even before other symptoms become noticeable.

The pain itself tends to feel deep and persistent, most commonly concentrated in the back, hips, ribs, or skull. Myeloma-related bone pain may feel different from typical muscle soreness, as some patients report that rest alone does not provide relief. Normal muscle soreness or a pulled ligament usually improves when you stop moving. Myeloma pain often doesn’t, and it may actually feel worse at night or with positional changes.

One particularly serious sign to watch for is a compression fracture in the spine, where a weakened vertebra collapses under normal pressure. This can cause a sudden, sharp increase in back pain and may signal that disease activity, including the possibility of M-protein rising in the bloodstream, has picked up again. If you notice a new pattern of bone pain that feels different from anything you’ve experienced before, bring it to your care team immediately.

Rising M-protein and biochemical relapse

Lab numbers can tell a story weeks, sometimes months, before your body does. That’s the core reality of biochemical relapse, and understanding it puts you ahead of CRAB symptoms that myeloma patients often don’t notice until they’re already disruptive.

Biochemical relapse is defined as a measurable rise in myeloma markers in your blood or urine without any accompanying physical symptoms. A steady increase in M-protein levels is often the first indicator of relapse, sometimes appearing months before you’d feel anything at all.

The two key markers your care team watches most closely are:

• M-spike (monoclonal protein). An abnormal protein produced by myeloma cells, detected through a serum protein electrophoresis (SPEP) test. A confirmed increase of 25% or more, or an absolute rise of at least 0.5 g/dL in M-spike, can signal relapse, per International Myeloma Working Group criteria.
• Bence-Jones protein: Myeloma light chains that spill into the urine. Elevated or rising levels of Bence-Jones protein (free light chains) can be used to monitor disease progression and detect relapse when M-spike levels are not measurable.

What your care team is specifically looking for is a doubling of these numbers over a short timeframe. A single elevated result matters less than a clear upward trend, which is exactly why consistent tracking is so valuable. You can log lab results over time, spot patterns between appointments, and bring clear trend data into conversations with your care team. And since relapse can also affect kidney function and calcium levels, the next section explores those connections in more detail.

The CRAB criteria. Hypercalcemia and kidney function

When multiple myeloma relapses, it doesn’t always announce itself through pain alone, blood chemistry shifts can quietly cause serious damage before you notice anything is wrong.

Hypercalcemia, the “C” in CRAB, happens when myeloma cells accelerate bone breakdown, flooding the bloodstream with calcium. That excess calcium doesn’t stay harmless. It causes brain fog, extreme thirst, nausea, and constipation. Hypercalcemia symptoms are often described as “moans, stones, and groans,” referring to constipation, kidney stones, and mental confusion. These symptoms can feel vague enough to dismiss, which is exactly what makes them dangerous. If you’re experiencing unexplained confusion or persistent digestive trouble alongside other warning signs, your care team needs to know.

Renal insufficiency, the “R,” is equally easy to miss in its early stages. Myeloma proteins, specifically light chains, clog the kidneys’ delicate filtering system in a process called cast nephropathy. Unlike biochemical relapse compared to clinical relapse, where the distinction is often made through lab work alone, kidney damage can produce physical signs you can observe yourself. Watch for foamy or sudsy urine, this is a specific indicator of protein leaking into the urine and should be reported to your care team immediately.

Swelling in the ankles or feet (edema) is another signal that kidney function may be declining, as the kidneys lose their ability to regulate fluid balance. Both signs deserve prompt attention. Understanding how the kidneys respond to treatment changes can help you stay ahead of complications before they escalate, and that awareness extends to how your body handles energy, which becomes especially critical when the immune system is also under strain.

Fatigue, infections, and the immune system

Bone marrow crowding is one of the most consequential, and least visible, effects of relapsing multiple myeloma, and it shows up in how you feel every single day.

Anemia is the “A” in the CRAB criteria, and it occurs because myeloma cells overwhelm the bone marrow’s capacity to produce healthy red blood cells. Cytopenias, or low blood counts, occur when myeloma cells interfere with the normal production of blood cells in the bone marrow. The result isn’t ordinary tiredness. It’s a profound lack of energy that can make walking across a room feel like a significant effort, often accompanied by shortness of breath and persistent pallor. This is different from normal fatigue, and it’s worth naming that distinction clearly when you talk to your care team.

As myeloma cells multiply, they crowd out normal plasma cells in the bone marrow and can suppress immune function, interfering with the body’s ability to produce healthy antibodies. That leaves you vulnerable in ways that aren’t always obvious. A pattern of recurring infections, pneumonia that returns within weeks, urinary tract infections that resist standard antibiotics, can signal that the immune system is failing to keep pace. Patients and care teams sometimes initially attribute these episodes to unrelated causes, particularly when classic signs like bone pain haven’t yet emerged to anchor the clinical picture.

Recognizing this pattern early matters. If you’re noticing that infections are becoming more frequent or harder to clear, that information belongs in your next conversation with your care team.

What you need to know. A summary of relapse signs

Recognizing a multiple myeloma relapse early depends on knowing which warning signs matter most and acting on them before they escalate. As previous sections have outlined, relapse can show up in blood chemistry, bone pain, immune function, and kidney health, sometimes all at once. Here’s a consolidated look at the key indicators your care team will want to know about.

Bone pain is often the first physical signal. New, persistent pain in the back or hips, especially pain that doesn’t resolve with rest, is a primary indicator of clinical relapse. Osteolytic lesions in bone pain point to myeloma cell activity and should never be dismissed as routine muscle soreness.

A rising M-protein level in blood or urine frequently signals a biochemical relapse before any physical symptoms begin. This is why routine lab monitoring is so important, it gives your care team an early window to reassess multiple myeloma treatment options before the disease progresses further.

Hypercalcemia-related symptoms, including confusion, nausea, and extreme thirst, can develop as calcium levels climb unchecked. At the same time, foamy urine and ankle swelling are critical signs of myeloma-related kidney dysfunction that require prompt evaluation. And frequent infections that are hard to treat suggest the cancer is crowding out healthy immune cells in the bone marrow, as covered in the previous section.

Taken together, these signs form a clear picture. Relapse is rarely a single event, it’s a pattern. And recognizing that pattern quickly is what opens the door to re-evaluating your personalized care plan, which is exactly what the next section addresses.

Taking action: personalized care and clinical trials

Recognizing warning signs is only the first step, what you do next determines how effectively you and your care team can get ahead of a multiple myeloma relapse. If any CRAB symptoms appear, contact your care team immediately. Don’t wait for a scheduled appointment. Early intervention gives your providers the best window to adjust treatment before the disease progresses further.

Relapse is also the right time to take a hard look at your personalized care plan. As multiple myeloma evolves, so can its genetic profile, meaning the approach that worked before may not be the most effective option now. Genomic retesting at relapse can reveal new mutations and help your care team identify therapies that are better matched to where the disease stands today, rather than where it was at diagnosis.

And relapse, while difficult, often opens access to treatment options that weren’t available before. Clinical trials for advanced immunotherapy approaches, including CAR-T cell therapy, are increasingly available to patients at first or subsequent relapse. Understanding what the CAR-T process actually involves, including the timeline and expectations, can help you have a more informed conversation with your care team.

Many oncologists emphasize that participating in a clinical trial may offer access to newer treatment approaches that could potentially benefit some patients with relapsed myeloma.

Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.